A 24-week, parallel-group, open-label, randomized trial comparing Telbivudine with Entecavir treatment in HBeAg-positive chronic hepatitis B patients.
Phase of Trial: Phase IV
Latest Information Update: 07 Dec 2012
At a glance
- Drugs Entecavir (Primary) ; Telbivudine (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 21 May 2012 Planned end date changed from 2 Oct 2008 to 30 Oct 2009 as reported by Chinese Clinical Trial Register.
- 20 Dec 2011 New trial record